English

Choose language

Back

  • Deutsch

  • English

  • Español

  • Français

  • Polski

  • Русский

  • Українська


English

Shares Pfizer

13.5%
Growth potential
35.7 $
Price per 1 share
USD
4.07%
Dividend income
Pfizer sold in lots of 1 pc.
Enter the number of securities
Order price:
Brokerage commission:
Transfer commission:
Working together for a healthier world
Why invest in Pfizer?
  • One of the world's largest pharma companies
  • Produces the most popular medical drug
  • Earnings increased by 2%, from $12.90B to $13.10B, in Q1 2019
  • Over €212B market cap as of now


1d
1w
1mo
6mths
All the time
Recommendations of the largest investment banks
SVB Leerink
Buy
40 $
16.06.2020
Standpoint Research
Buy
27.02.2020
Barclays
Hold
36 $
27.02.2020
Mizuho
Buy
06.02.2020
Financial indicators
Capitalization
267.23B $
P / E
11.68
Profit
53.37B $
Net profit
41.96B $
The general recommendation of investment banks

Hold

Based on the analytics from 19 of the world's largest investment banks over the past 3 months

Forecasted prices

Target price

41.27 $

(15.59% Growth potential)

Based on the data from 19 of the leading investment banks

An American corporation Pfizer Inc. specializes in manufacturing pharmaceutical drugs, such as Diflucan, Celebrex, Viagra. The company is almost 170 years old, and its growth peak was at the end of the 20th century when new and highly efficient results of "Pfizer" developments entered the market. The beginning of the 19th century was the time of mergers and acquisitions with the largest one being with an Irish company Allergan. Up to now, the company's existence was based on several successful developments; however, in future, it aims at abandoning this strategy and start investing in biotechnologies, for which purpose it purchased Wyeth company. A special attention will be paid to biological drugs of natural origin that slow aging. According to statistics, Pfizer accounts for more than 6% of the global drug market - the company is the leader of its sector. The company capitalization amounts to $190 billion; in 2017, the net profit amounted to $13.7 billion with annual turnover facing a slight decrease. Earlier, the stocks had been falling in price for several years, probably, due to a prolonged reorganization of the company; however, since 2016, an upward trend has become visible. As far as the further destiny of the Pfizer stocks is concerned, analysts stick to moderately optimistic opinion connected with a clear viewpoint of Ian Read who became the President of the company in 2010. His whole career has been dedicated to Pfizer; he got the highest position on the back of reorganization, has completed it and returned the company back to high financial results.

Receive ideas for profitable investments - faster than the market

We will be sending you a letter once a week with the most relevant information

Congratulations!

Now you will always be aware of which stocks are more profitable to invest in